Abstract | OBJECTIVE: For rarity of thymic carcinoma, no definitive chemotherapeutic regimen has been established in second- or further-line settings. The aim of this study was to evaluate the feasibility and safety of paclitaxel plus carboplatin in advanced thymic carcinoma as second- or further-line treatment in our institute. METHODS: RESULTS: Twelve patients were included in current study. Four patients achieved stable disease (SD), and three achieved partial response (PR), representing a response rate of 25.0% and disease control rate (DCR) of 58.3%. Median progression-free survival (PFS) and overall survival (OS) were 3.5 and 24.0 months, respectively. The toxicities associated with the paclitaxel plus carboplatin was generally acceptable. CONCLUSIONS:
|
Authors | Zhengbo Song |
Journal | Journal of thoracic disease
(J Thorac Dis)
Vol. 6
Issue 12
Pg. 1808-12
(Dec 2014)
ISSN: 2072-1439 [Print] China |
PMID | 25589977
(Publication Type: Journal Article)
|